跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,228 条关于
“selective EP300 degrader”
全部
6,228
临床试验
3,201
药物
396
机构
12
资讯
2,619
11个月前
Foghorn Therapeutics Reports Breakthrough Progress in Selective ARID1B Degrader for Cancer Treatment
10个月前
Foghorn Therapeutics Advances Multi-Target Protein Degrader Pipeline with FHD-909 Phase 1 Trial Progressing
去年
Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation
8个月前
Foghorn Therapeutics Secures $50 Million Financing to Advance First-in-Class Cancer Pipeline
去年
Advancing NLRP3 Inhibition: Novel Chemotypes Emerge in Clinical Trials
9个月前
Opna Bio's Zavabresib Receives FDA Orphan Drug Designation for Myelofibrosis Treatment
9个月前
Prelude Therapeutics Unveils Novel JAK2V617F-Selective Inhibitor and mCALR-Targeted Therapy for Myeloproliferative Neoplasms
去年
Fate Therapeutics Presents Promising Early Data for FT825/ONO-8250 CAR-T Therapy in Solid Tumors
2年前
Plexium Advances First-in-Class IKZF2 Degrader PLX-4545 into Phase 1 Clinical Trial
2年前
Prelude Therapeutics' PRT3789 Shows Promise in SMARCA4-Mutated Cancers
第 1 页,共 262 页
上一页
下一页